search
Back to results

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy (REBIRTH)

Primary Purpose

Peripartum Cardiomyopathy, Postpartum

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Bromocriptine
Placebo
Guideline Directed Medical Therapy for Heart Failure (GDMT)
Rivaroxaban
Second Placebo
Sponsored by
Dennis M. McNamara, MD, MS
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripartum Cardiomyopathy, Postpartum

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Presentation with a new diagnosis of peripartum cardiomyopathy
  2. Post-delivery and within the first 5 months post-partum.
  3. Clinical assessment of an LVEF < or =0.35 within 2 weeks of randomization
  4. Age > or = 18.

Exclusion Criteria:

  1. Previous diagnosis of cardiomyopathy, valvular disease or congenital heart disease (with the exception of women with a history of peripartum cardiomyopathy with complete recovery and a documented LVEF > 0.55 prior to or in early pregnancy)
  2. Refractory hypertension (Systolic >160 or Diastolic > 95) either at the time of enrollment or at the time of the qualifying LVEF.
  3. Postpartum women currently breastfeeding and planning to continue.
  4. Evidence of coronary artery disease (>50% stenosis of major epicardial vessel or positive non-invasive stress test)
  5. Previous cardiac transplant
  6. Current durable LVAD support
  7. Currently requiring support with extracorporeal membrane oxygenation (ECMO)
  8. Current history of alcohol or drug abuse
  9. Chemotherapy or chest radiation within 5 years of enrollment
  10. Evidence of ongoing bacterial septicemia
  11. Medical, social or psychiatric condition which limit the ability to comply with follow-up.

Sites / Locations

  • University of Alabama BirminghamRecruiting
  • University of Arizona Sarver Heart CenterRecruiting
  • Cedars-Sinai Medical CenterRecruiting
  • University of California Irvine HealthRecruiting
  • Stanford UniversityRecruiting
  • University of Colorado Anschutz Medical CampusRecruiting
  • University of FloridaRecruiting
  • Mayo Clinic, FloridaRecruiting
  • Northwestern UniversityRecruiting
  • University of Illinois Health Heart CenterRecruiting
  • Indiana University/Indiana University HealthRecruiting
  • Ascension St. Vincent Heart CenterRecruiting
  • University of Kentucky, Gill Heart & Vascular InstituteRecruiting
  • Louisiana State UniversityRecruiting
  • Johns Hopkins UniversityRecruiting
  • Massachusetts General HospitalRecruiting
  • Brigham and Women's HospitalRecruiting
  • University of MichiganRecruiting
  • Henry Ford Health SystemRecruiting
  • Saint Luke's Hospital of Kansas CityRecruiting
  • Washington University School of MedicineRecruiting
  • Albert Einstein College of Medicine/ Montefiore Medical CenterRecruiting
  • Columbia University Irving Medical CenterRecruiting
  • University of RochesterRecruiting
  • University Hospitals, Cleveland Medical CenterRecruiting
  • Cleveland ClinicRecruiting
  • Oklahoma university Health Science CenterRecruiting
  • Lehigh Valley Health NetworkRecruiting
  • Penn State Hershey Medical CenterRecruiting
  • University of PennsylvaniaRecruiting
  • University of Pittsburgh Medical CenterRecruiting
  • Rhode Island HospitalRecruiting
  • VanderbiltRecruiting
  • University of Texas Southwestern Medical CenterRecruiting
  • University of Texas Health San AntonioRecruiting
  • Intermountain Medical CenterRecruiting
  • University of Vermont Medical CenterRecruiting
  • University of Washington Medical CenterRecruiting
  • Medical College of WisconsinRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Placebo Comparator

Other

Arm Label

Bromocriptine Treatment Arm

Placebo Arm

Breastfeeding Observational Cohort

Arm Description

100 Women in the Treatment Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of bromocriptine administered orally as 2.5 mg twice daily for 2 weeks then 2.5mg once daily for 6 weeks. Women not on clinical anticoagulation will also receive prophylactic anticoagulation with rivaroxaban 10 mg once daily for 8 weeks while on bromocriptine.

100 Women in the Placebo Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of a placebo administered orally twice daily for 2 weeks then once daily for 6 weeks. Women not on clinical anticoagulation will not receive rivaroxaban but will instead receive a second placebo for 8 weeks.

Up to 50 women meeting all other criteria but excluded from REBIRTH due to an intent to continue to breastfeed will be enrolled in an observational cohort. They will receive guideline directed medical therapy with no additional interventions and will have the same follow up and assessment of myocardial recovery by echocardiogram at 6 and 12 months post entry as women in the randomized trial.

Outcomes

Primary Outcome Measures

Left ventricular ejection fraction (LVEF) at 6 months post entry as determined by echocardiography

Secondary Outcome Measures

Left ventricular ejection fraction (LVEF) at 12 months post entry as determined by echocardiography
Survival free from cardiac transplantation or implantation of a durable left ventricular assist device (LVAD)
Survival free from heart failure hospitalization

Full Information

First Posted
December 9, 2021
Last Updated
August 1, 2023
Sponsor
Dennis M. McNamara, MD, MS
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
search

1. Study Identification

Unique Protocol Identification Number
NCT05180773
Brief Title
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Acronym
REBIRTH
Official Title
Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 27, 2022 (Actual)
Primary Completion Date
June 30, 2026 (Anticipated)
Study Completion Date
December 31, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Dennis M. McNamara, MD, MS
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort.
Detailed Description
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized trial of bromocriptine therapy to evaluate its impact on myocardial recovery. All women will have an assessment of LVEF demonstrating an LVEF < or = 0.35 within 4 weeks prior to consent. At entry they will then have an assessment of LVEF by echocardiogram which will be repeated at 6- and 12-months post study entry. Subjects in the randomized trial will be randomized to standard medical therapy for heart failure plus placebo or standard therapy plus 8 weeks of bromocriptine (2.5 mg twice daily for 2 weeks then once 2.5 mg daily for 6 weeks). Women receiving bromocriptine not currently on anticoagulation will also receive prophylactic anticoagulation with rivaroxaban 10 mg once daily for 8 weeks. Primary analysis will compare LVEF at 6 months post entry in the women receiving standard therapy plus bromocriptine to those on standard therapy plus placebo (controlling for initial baseline LVEF). Secondary endpoints will analyze the LVEF in both treatment groups at 12 months post randomization. In addition, subjects will be followed for up to 3 years post randomization and survival free from a major event (cardiac transplantation or durable LVAD implantation) and survival free from heart failure hospitalization will be compared by treatment group. The benefits of bromocriptine are theoretically related to suppression of prolactin secretion. Breastfeeding increases prolactin levels, and whether continued breastfeeding will impact myocardial recovery in women with peripartum cardiomyopathy remains unknown. As bromocriptine prevents breastfeeding, women who want to continue breastfeeding are excluded from the randomized trial. Up to 50 women meeting all other criteria but excluded from REBIRTH due to an intent to continue to breastfeed will be enrolled in an observational cohort. They will receive standard therapy with no additional intervention and will have the same follow up and assessment of myocardial recovery by echocardiogram at 6- and 12-months post entry as women in the randomized trial. Blood will be obtained at entry for DNA banking, and analysis of serum, and whole blood RNA . Additional serum and whole blood RNA will be banked at 1-, 3-, and 6-months post randomization. This investigation will evaluate the impact of bromocriptine therapy on the levels of intact 23 kilodalton (kDa) prolactin and the 16 kDa prolactin fragment, as well as microRNA (miR) 146a. The biomarker analysis will also be performed in the observational cohort of women excluded due to continued breast feeding. The impact of these biomarkers on outcomes in both the treatment and control groups as well as the observational cohort excluded due to breastfeeding will be examined. A core laboratory will analyze all echocardiograms. In addition to quantifying the LVEF at entry, 6 months and 12 months post entry, the core will evaluate global longitudinal strain (LGS) and remodeling (LV volumes) at entry as predictors of outcome and drug response. They will also evaluate the impact of therapy on LGS and LV volumes at 6- and 12-months post randomization.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripartum Cardiomyopathy, Postpartum

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
200 women meeting all inclusion and exclusion criterial will be randomized in a placebo controlled double blind investigation evaluating the impact of bromocriptine on outcomes for women newly diagnosed with peripartum cardiomyopathy. An additional 50 women in excluded from the trial due to an intent to continue breastfeeding but meeting all other criteria will be enrolled in an observational cohort. All women with receive standard medical care for peripartum cardiomyopathy and will be followed for up to three years.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Once consent is obtained the screening sheet will be submitted to the data coordinating center. This will be reviewed to ensure the subject meets criteria for randomization. Subjects will be randomized by the Data Coordinating Center (DCC).
Allocation
Randomized
Enrollment
250 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bromocriptine Treatment Arm
Arm Type
Active Comparator
Arm Description
100 Women in the Treatment Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of bromocriptine administered orally as 2.5 mg twice daily for 2 weeks then 2.5mg once daily for 6 weeks. Women not on clinical anticoagulation will also receive prophylactic anticoagulation with rivaroxaban 10 mg once daily for 8 weeks while on bromocriptine.
Arm Title
Placebo Arm
Arm Type
Placebo Comparator
Arm Description
100 Women in the Placebo Arm will receive guideline directed medical therapy for heart failure plus 8 weeks of a placebo administered orally twice daily for 2 weeks then once daily for 6 weeks. Women not on clinical anticoagulation will not receive rivaroxaban but will instead receive a second placebo for 8 weeks.
Arm Title
Breastfeeding Observational Cohort
Arm Type
Other
Arm Description
Up to 50 women meeting all other criteria but excluded from REBIRTH due to an intent to continue to breastfeed will be enrolled in an observational cohort. They will receive guideline directed medical therapy with no additional interventions and will have the same follow up and assessment of myocardial recovery by echocardiogram at 6 and 12 months post entry as women in the randomized trial.
Intervention Type
Drug
Intervention Name(s)
Bromocriptine
Other Intervention Name(s)
Parlodel, Cycloset
Intervention Description
Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
Intervention Type
Drug
Intervention Name(s)
Guideline Directed Medical Therapy for Heart Failure (GDMT)
Intervention Description
GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
Intervention Type
Drug
Intervention Name(s)
Rivaroxaban
Other Intervention Name(s)
Xarelto
Intervention Description
Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.
Intervention Type
Drug
Intervention Name(s)
Second Placebo
Other Intervention Name(s)
Placebo
Intervention Description
Subjects not on anticoagulation clinically who are randomized to placebo (rather than bromocriptine) will receive a second placebo one tablet by mouth daily for 8 weeks.
Primary Outcome Measure Information:
Title
Left ventricular ejection fraction (LVEF) at 6 months post entry as determined by echocardiography
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Left ventricular ejection fraction (LVEF) at 12 months post entry as determined by echocardiography
Time Frame
12 months
Title
Survival free from cardiac transplantation or implantation of a durable left ventricular assist device (LVAD)
Time Frame
3 years
Title
Survival free from heart failure hospitalization
Time Frame
3 years
Other Pre-specified Outcome Measures:
Title
Global longitudinal strain (GLS) at 6 months post entry as determined by echocardiography
Time Frame
6 months
Title
Global longitudinal strain (GLS) at 12 months post entry as determined by echocardiography
Time Frame
12 months
Title
Left ventricular volumes at 6 months post entry as determined by echocardiography
Time Frame
6 months
Title
Left ventricular volumes at 12 months post entry as determined by echocardiography
Time Frame
12 months

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Women recently diagnosed with peripartum cardiomyopathy who are 18 years or older and are within 5 months of postpartum.
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Presentation with a new diagnosis of peripartum cardiomyopathy Post-delivery and within the first 5 months post-partum. Clinical assessment of an LVEF < or =0.35 within 4 weeks of randomization Age > or = 18. Exclusion Criteria: Previous diagnosis of cardiomyopathy, valvular disease or congenital heart disease (with the exception of women with a history of peripartum cardiomyopathy with complete recovery and a documented LVEF > 0.55 prior to or in early pregnancy) Refractory hypertension (Systolic >160 or Diastolic > 95) either at the time of enrollment or at the time of the qualifying LVEF. Postpartum women currently breastfeeding and planning to continue. Evidence of coronary artery disease (>50% stenosis of major epicardial vessel or positive non-invasive stress test) Previous cardiac transplant Current durable LVAD support Currently requiring support with extracorporeal membrane oxygenation (ECMO) Current history of alcohol or drug abuse Chemotherapy or chest radiation within 5 years of enrollment Evidence of ongoing bacterial septicemia Medical, social or psychiatric condition which limit the ability to comply with follow-up.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dennis McNamara, MD
Phone
412-802-3131
Email
mcnamaradm@upmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dennis McNamara
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35205
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gina Horton
Phone
205-224-7502
Email
ghorton@uabmc.edu
First Name & Middle Initial & Last Name & Degree
Elizabeth Kaufman
Phone
205-234-9610
Email
erehrhard@uabmc.edu
First Name & Middle Initial & Last Name & Degree
Gretchen Wells, MD
Facility Name
University of Arizona Sarver Heart Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lizzette Cruz
Phone
520-626-2471
Email
marquez@shc.arizona.edu
First Name & Middle Initial & Last Name & Degree
Elizabeth Juneman, MD
Facility Name
Cedars-Sinai Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Odette Chida Ibarra
Phone
310-423-9459
Email
odette.chidaibarra@cshs.org
First Name & Middle Initial & Last Name & Degree
Janet Wei, MD
Facility Name
University of California Irvine Health
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Linh Huỳnh, MPH
Phone
714-456-6155
Email
plhuynh@hs.uci.edu
First Name & Middle Initial & Last Name & Degree
Afshan Hameed, MD
Facility Name
Stanford University
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tamara Bazouzi
Phone
650-723-7024
Email
bazouzit@stanford.edu
First Name & Middle Initial & Last Name & Degree
Abha Khandelwal, M.D.
Facility Name
University of Colorado Anschutz Medical Campus
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emanuel Gebreab, BS
Phone
303-724-5683
Email
Emanuel.Gebreab@cuanschutz.edu
First Name & Middle Initial & Last Name & Degree
Josephine Chou, MD
Facility Name
University of Florida
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32608
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shaunmonique Clark
Phone
352-273-8933
Email
Shaunmonique.Clark@medicine.ufl.edu
First Name & Middle Initial & Last Name & Degree
Alex Parker, MD
Facility Name
Mayo Clinic, Florida
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Indira Becerrit Rojas
Phone
904-953-4832
Email
Becerrit.Indira@mayo.edu
First Name & Middle Initial & Last Name & Degree
Demilade Adedinsewo, MD, MPH
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lauren Murrin
Phone
312-926-1096
Email
lauren.murrin@nm.org
First Name & Middle Initial & Last Name & Degree
Priya Freaney, MD
Facility Name
University of Illinois Health Heart Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Muriel Chen
Phone
312-355-1861
Email
yining@uic.edu
First Name & Middle Initial & Last Name & Degree
Joan Briller, MD
Facility Name
Indiana University/Indiana University Health
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Srdjan Kurbalija
Phone
317-962-9904
Email
skurbalija@iuhealth.org
First Name & Middle Initial & Last Name & Degree
Maya Guglin, MD
Facility Name
Ascension St. Vincent Heart Center
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46260
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Renick
Phone
317-338-6152
Email
anne.renick@ascension.org
First Name & Middle Initial & Last Name & Degree
Regina Margiotti
Phone
317-338-6151
Email
RAMARGIO@ascension.org
First Name & Middle Initial & Last Name & Degree
Mary Walsh, M.D.
Facility Name
University of Kentucky, Gill Heart & Vascular Institute
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer Isaacs
Phone
859-323-4738
Email
Jennifer.isaacs@uky.edu
First Name & Middle Initial & Last Name & Degree
Navin Rajagopalan, M.D.
Facility Name
Louisiana State University
City
Shreveport
State/Province
Louisiana
ZIP/Postal Code
71103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Monicah Jepkemboi
Phone
318-675-8882
Email
monicah.jepkemboi@lsuhs.edu
First Name & Middle Initial & Last Name & Degree
Kalgi Modi, MD
Facility Name
Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yavette Goldsborough
Phone
410-614-4449
Email
ygoldsb1@jhmi.edu
First Name & Middle Initial & Last Name & Degree
Nisha Gilotra, M.D.
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brandon McBay, MPH
Phone
617-726-5554
Email
bmcbay@mgh.harvard.edu
First Name & Middle Initial & Last Name & Degree
Nandita S. Scott, MD FACC
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Prem Patel
Phone
617-732-7179
Email
ppatel50@partners.org
First Name & Middle Initial & Last Name & Degree
Michael Givertz, M.D.
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kavita Shah
Phone
734-998-9971
Email
skavita@med.umich.edu
First Name & Middle Initial & Last Name & Degree
Melinda Davis, MD
Facility Name
Henry Ford Health System
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jodi Baxter
Phone
313-916-3613
Email
Jbaxter2@hfhs.org
First Name & Middle Initial & Last Name & Degree
Ryhm Radjef, M.D.
Facility Name
Saint Luke's Hospital of Kansas City
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64154
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rosann Gans, RN
Phone
816-932-6122
Email
rgans@saint-lukes.org
First Name & Middle Initial & Last Name & Degree
Anna Grodzinsky, MD,MSc
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Annie Dirks
Email
aplatts@wustl.edu
First Name & Middle Initial & Last Name & Degree
Gregory Ewald, M.D.
Facility Name
Albert Einstein College of Medicine/ Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brandon Johnson
Phone
718-920-8731
Email
brajohnson@montefiore.org
First Name & Middle Initial & Last Name & Degree
Govindi Harricharran
Phone
718-920-7374
Email
gharrichar@montefiore.org
First Name & Middle Initial & Last Name & Degree
Sandhya Murthy, M.D.
First Name & Middle Initial & Last Name & Degree
Diana S. Wolfe, MD, MPH
Facility Name
Columbia University Irving Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barbara Alvarez
Phone
212-303-1368
Email
bsa2133@cumc.columbia.edu
First Name & Middle Initial & Last Name & Degree
Jennifer Haythe, MD
Facility Name
University of Rochester
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lori Caufield, RN BSN CCRC
Phone
585-273-4956
Email
lori_caufield@urmc.rochester.edu
First Name & Middle Initial & Last Name & Degree
Jeffrey Alexis, MD
Facility Name
University Hospitals, Cleveland Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emily Mullenax
Phone
216-844-3852
Email
Emily.Mullenax@UHhospitals.org
First Name & Middle Initial & Last Name & Degree
Chantal ElAmm, MD
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Barbara Gus
Phone
216-445-6552
Email
gusb@ccf.org
First Name & Middle Initial & Last Name & Degree
Eileen Hsich, MD
Facility Name
Oklahoma university Health Science Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Natalia W. Serrano
Phone
405-271-4742
Ext
37520
Email
Natalia-WellsSerrano@ouhsc.edu
First Name & Middle Initial & Last Name & Degree
Tarun Dasari, M.D.
Facility Name
Lehigh Valley Health Network
City
Allentown
State/Province
Pennsylvania
ZIP/Postal Code
18103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Traci Eichelberger, RN, CCRC
Phone
610-402-5862
Email
Traci_L.Eichelberger@lvhn.org
First Name & Middle Initial & Last Name & Degree
Amy Ahnert, M.D.
Facility Name
Penn State Hershey Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katie Loffredo
Phone
717-531-6855
Email
kloffredo@pennstatehealth.psu.edu
First Name & Middle Initial & Last Name & Degree
Matthew Rutt
Email
mrutt3@pennstatehealth.psu.edu
First Name & Middle Initial & Last Name & Degree
John P. Boehmer, M.D.
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kevin Dougherty
Phone
215-662-2243
Email
Kevin.dougherty@pennmedicine.upenn.edu
First Name & Middle Initial & Last Name & Degree
Jennifer Lewey, MD
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15237
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dennis McNamara, MD
Phone
412-802-3131
Email
mcnamaradm@upmc.edu
First Name & Middle Initial & Last Name & Degree
Donna Simpson, CRNP, MPH
Phone
412-692-3522
Email
simpsondm@upmc.edu
First Name & Middle Initial & Last Name & Degree
Dennis McNamara, MD
Facility Name
Rhode Island Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Catherine Gordon, RN
Phone
401-444-8598
Email
cgordon@lifespan.org
First Name & Middle Initial & Last Name & Degree
Kelly Franchetti, RN
Phone
401-444-9828
Email
kfranchetti@lifespan.org
First Name & Middle Initial & Last Name & Degree
Athena Poppas, MD
Facility Name
Vanderbilt
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vicky Yurisic, RN, MSN
Phone
615-343-9071
Email
victoria.yurisic@vumc.org
First Name & Middle Initial & Last Name & Degree
Julie Damp, MD
Facility Name
University of Texas Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carolyn Kelly, RN
Phone
214-645-8040
Email
carolyn.kelly@utsouthwestern.edu
First Name & Middle Initial & Last Name & Degree
Sonia Garg, M.D.
Facility Name
University of Texas Health San Antonio
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Edgar Rafael Infante
Phone
210-450-7305
Email
infantee@uthscsa.edu
First Name & Middle Initial & Last Name & Degree
Ildiko Agoston, MD
Facility Name
Intermountain Medical Center
City
Murray
State/Province
Utah
ZIP/Postal Code
84107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lindsey Bevan
Phone
801-507-4889
Email
Lindsey.Bevan@imail.org
First Name & Middle Initial & Last Name & Degree
Rami Alharethi, M.D.
Facility Name
University of Vermont Medical Center
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Meghan Sesera, RN
Phone
802-847-4746
Email
meghan.sesera@uvmhealth.org
First Name & Middle Initial & Last Name & Degree
Friederike Keating, MD
Facility Name
University of Washington Medical Center
City
Seattle
State/Province
Washington
ZIP/Postal Code
98195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Adele Stefanowicz
Phone
206-616-6768
Email
amstef99@cardiology.washington.edu
First Name & Middle Initial & Last Name & Degree
April Stempien-Otero, MD, FACC
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shelley Schultz
Phone
414-955-6784
Email
sschultz@mcw.edu
First Name & Middle Initial & Last Name & Degree
Sarah Thordsen, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
36202537
Citation
Briller JE. Echocardiographic Screening in Hypertensive Pregnancy Disorders: Probing the Window of Opportunity. J Am Coll Cardiol. 2022 Oct 11;80(15):1477-1479. doi: 10.1016/j.jacc.2022.08.717. No abstract available.
Results Reference
derived

Learn more about this trial

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

We'll reach out to this number within 24 hrs